Search Results - "Desrame, Jérôme"

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study by André, Thierry, Tougeron, David, Piessen, Guillaume, de la Fouchardière, Christelle, Louvet, Christophe, Adenis, Antoine, Jary, Marine, Tournigand, Christophe, Aparicio, Thomas, Desrame, Jérôme, Lièvre, Astrid, Garcia-Larnicol, Marie-Line, Pudlarz, Thomas, Cohen, Romain, Memmi, Salomé, Vernerey, Dewi, Henriques, Julie, Lefevre, Jérémie H, Svrcek, Magali

“…In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of…”
Get full text

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial by André, Thierry, Vernerey, Dewi, Mineur, Laurent, Bennouna, Jaafar, Desrame, Jérôme, Faroux, Roger, Fratte, Serge, Hug de Larauze, Marine, Paget-Bailly, Sophie, Chibaudel, Benoist, Bez, Jeremie, Dauba, Jérôme, Louvet, Christophe, Lepere, Céline, Dupuis, Olivier, Becouarn, Yves, Mabro, May, Egreteau, Joëlle, Bouche, Olivier, Deplanque, Gaël, Ychou, Marc, Galais, Marie Pierre, Ghiringhelli, François, Dourthe, Louis Marie, Bachet, Jean-Baptiste, Khalil, Ahmed, Bonnetain, Franck, de Gramont, Aimery, Taieb, Julien

“…Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages…”
Get full text

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study by Kim, Stefano, François, Eric, André, Thierry, Samalin, Emmanuelle, Jary, Marine, El Hajbi, Farid, Baba-Hamed, Nabil, Pernot, Simon, Kaminsky, Marie-Christine, Bouché, Olivier, Desrame, Jérôme, Zoubir, Mustapha, Ghiringhelli, François, Parzy, Aurélie, De La Fouchardiere, Christelle, Smith, Denis, Deberne, Mélanie, Spehner, Laurie, Badet, Nicolas, Adotevi, Olivier, Anota, Amélie, Meurisse, Aurélia, Vernerey, Dewi, Taieb, Julien, Vendrely, Véronique, Buecher, Bruno, Borg, Christophe

“…The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades. Currently, there is no validated treatment for…”
Get full text

Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study by Phelip, Jean-Marc, Edeline, Julien, Blanc, Jean-Frédéric, Barbier, Emilie, Michel, Pierre, Bourgeois, Vincent, Neuzillet, Cindy, Malka, David, Manfredi, Sylvain, Desrame, Jérôme

“…Combination of cisplatine and Gemcitabine (CisGem) is the reference 1st line Chemotherapy in patients with advanced biliary cancer. FOLFIRINOX demonstrated an…”
Get full text

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial by Taieb, Julien, Taly, Valérie, Henriques, Julie, Bourreau, Camille, Mineur, Laurent, Bennouna, Jaafar, Desrame, Jérôme, Louvet, Christophe, Lepere, Céline, Mabro, May, Egreteau, Joëlle, Bouche, Olivier, Mulot, Claire, Hormigos, Katia, Chaba, Kariman, Mazard, Thibault, de Gramont, Aimery, Vernerey, Dewi, André, Thierry, Laurent-Puig, Pierre

“…Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized in…”
Get full text

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study by Phelip, Jean Marc, Desrame, Jérôme, Edeline, Julien, Barbier, Emilie, Terrebonne, Eric, Michel, Pierre, Perrier, Hervé, Dahan, Laetitia, Bourgeois, Vincent, Akouz, Faiza Khemissa, Soularue, Emilie, Ly, Valérie Lebrun, Molin, Yann, Lecomte, Thierry, Ghiringhelli, François, Coriat, Romain, Louafi, Samy, Neuzillet, Cindy, Manfredi, Sylvain, Malka, David

“…Whether triplet chemotherapy is superior to doublet chemotherapy in advanced biliary tract cancer (BTC) is unknown. In this open-label, randomized phase II-III…”
Get full text

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study by Kim, Stefano, Vendrely, Véronique, Saint, Angélique, André, Thierry, Vaflard, Pauline, Samalin, Emmanuelle, Pernot, Simon, Bouché, Oliver, Zubir, Mustapha, Desrame, Jérôme, de la Fouchardière, Christelle, Smith, Denis, Ghiringhelli, François, Vienot, Angélique, Jacquin, Marion, Klajer, Elodie, Nguyen, Thierry, François, Éric, Taieb, Julien, Le Malicot, Karine, Vernerey, Dewi, Meurisse, Aurélia, Borg, Christophe

“…Triplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively…”
Get full text

Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6) by Lefevre, Jérémie H, Mineur, Laurent, Kotti, Salma, Rullier, Eric, Rouanet, Philippe, de Chaisemartin, Cécile, Meunier, Bernard, Mehrdad, Jafari, Cotte, Eddy, Desrame, Jérome, Karoui, Mehdi, Benoist, Stéphane, Kirzin, Sylvain, Berger, Anne, Panis, Yves, Piessen, Guillaume, Saudemont, Alain, Prudhomme, Michel, Peschaud, Frédérique, Dubois, Anne, Loriau, Jérome, Tuech, Jean-Jacques, Meurette, Guillaume, Lupinacci, Renato, Goasgen, Nicolas, Parc, Yann, Simon, Tabassome, Tiret, Emmanuel

“…Purpose A pathologic complete response (pCR; ypT0N0) of a rectal tumor after neoadjuvant radiochemotherapy (RCT) is associated with an excellent prognosis…”
Get full text

Retroperitoneal fibrosis, sclerosing pancreatitis and bronchiolitis obliterans with organizing pneumonia by Duvic, Christian, Desrame, Jérôme, Lévêque, Christophe, Nedelec, Georges

Get full text

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues by Brieau, Bertrand, Dahan, Laetitia, De Rycke, Yann, Boussaha, Tarek, Vasseur, Philippe, Tougeron, David, Lecomte, Thierry, Coriat, Romain, Bachet, Jean‐Baptiste, Claudez, Pierre, Zaanan, Aziz, Soibinet, Pauline, Desrame, Jérome, Thirot‐Bidault, Anne, Trouilloud, Isabelle, Mary, Florence, Marthey, Lysiane, Taieb, Julien, Cacheux, Wulfran, Lièvre, Astrid

“…BACKGROUND Few data are available on second‐line chemotherapy (CT2) for advanced biliary tract cancer (ABTC). The aim of this multicenter study was to describe…”
Get full text

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study by Williet, Nicolas, Saint, Angélique, Pointet, Anne-Laure, Tougeron, David, Pernot, Simon, Pozet, Astrid, Bechade, Dominique, Trouilloud, Isabelle, Lourenco, Nelson, Hautefeuille, Vincent, Locher, Christophe, Desrame, Jérome, Artru, Pascal, Thirot Bidault, Anne, Le Roy, Bertrand, Pezet, Denis, Phelip, Jean-Marc, Taieb, Julien

“…Background: Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC)…”
Get full text

Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years’ Follow-up Results of the Greccar-6 Randomized Multicenter Trial by Lefèvre, Jérémie H, Mineur, Laurent, Cachanado, Marine, Denost, Quentin, Rouanet, Philippe, de Chaisemartin, Cécile, Meunier, Bernard, Mehrdad, Jafari, Cotte, Eddy, Desrame, Jérome, Karoui, Mehdi, Benoist, Stéphane, Kirzin, Sylvain, Berger, Anne, Panis, Yves, Piessen, Guillaume, Saudemont, Alain, Prudhomme, Michel, Peschaud, Frédérique, Dubois, Anne, Loriau, Jérome, Tuech, Jean-Jacques, Meurette, Guillaume, Lupinacci, Renato, Goasguen, Nicolas, Creavin, Ben, Simon, Tabassome, Parc, Yann

“…OBJECTIVE:The aim of this study was to report the 3-year survival results of the GRECCAR-6 trial. SUMMARY BACKGROUND DATA:Current data on the effect of an…”
Get full text

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial by Kim, Stefano, Buecher, Bruno, André, Thierry, Jary, Marine, Bidard, François-Clément, Ghiringhelli, François, François, Éric, Taieb, Julien, Smith, Denis, de la Fouchardière, Christelle, Desramé, Jérôme, Samalin, Emmanuelle, Parzy, Aurélie, Baba-Hamed, Nabil, Bouché, Olivier, Tougeron, David, Dahan, Laëtitia, El Hajbi, Farid, Jacquin, Marion, Rebucci-Peixoto, Magali, Spehner, Laurie, Vendrely, Véronique, Vernerey, Dewi, Borg, Christophe

“…Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced…”
Get full text

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study by Kim, Stefano, Ghiringhelli, Francois, de la Fouchardière, Christelle, Evesque, Ludovic, Smith, Denis, Badet, Nicolas, Samalin, Emmanuelle, Lopez-Trabada Ataz, Daniel, Parzy, Aurelie, Desramé, Jérôme, Baba Hamed, Nabil, Buecher, Bruno, Tougeron, David, Bouché, Olivier, Dahan, Laetitia, Chibaudel, Benoist, El Hajbi, Farid, Mineur, Laurent, Dubreuil, Olivier, Ben Abdelghani, Meher, Pecout, Solange, Bibeau, Frederic, Herfs, Michael, Garcia, Marie-Line, Meurisse, Aurelia, Vernerey, Dewi, Taïeb, Julien, Borg, Christophe

“…The modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen has shown efficacy and safety as first-line treatment for advanced squamous cell carcinoma…”
Get full text

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study by Andre, Thierry, Tougeron, David, Piessen, Guillaume, De La Fouchardiere, Christelle, Louvet, Christophe, Adenis, Antoine, Jary, Marine, Tournigand, Christophe, Aparicio, Thomas, Desrame, Jérôme, Lièvre, Astrid, Garcia-Larnicol, Marie-Line, Pudlarz, Thomas, Henriques, Julie, Cohen, Romain, Lefevre, Jérémie, Svrcek, Magali

“…Abstract only 244 Background: In pts with resectable gastric adenocarcinoma or OGA, radical surgery is the only curative option and perioperative chemotherapy…”
Get full text

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma by McLellan, Paul, Henriques, Julie, Ksontini, Feryel, Doat, Solène, Hammel, Pascal, Desrame, Jérome, Trouilloud, Isabelle, Louvet, Christophe, Pietrasz, Daniel, Vernerey, Dewi, Bachet, Jean-Baptiste

“…•What is already known on this subject?○Neutrophils-to-lymphocytes ratio (NLR) at diagnosis is an independent prognosis marker in metastatic pancreatic…”
Get full text

Efficacy of EUS-guided hepaticogastrostomy in prolonging survival of patients with perihilar cholangiocarcinoma by Schoch, Armelle, Lisotti, Andrea, Walter, Thomas, Fumex, Fabien, Leblanc, Sarah, Artru, Pascal, Desramé, Jérôme, Brighi, Nicole, Marsot, Julien, Souquet, Jean-Christophe, Napoléon, Bertrand

Get full text

Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study by Pointet, Anne-Laure, Tougeron, David, Pernot, Simon, Pozet, Astrid, Béchade, Dominique, Trouilloud, Isabelle, Lourenco, Nelson, Hautefeuille, Vincent, Locher, Christophe, Williet, Nicolas, Desrame, Jérôme, Artru, Pascal, Soularue, Emilie, Le Roy, Bertrand, Taieb, Julien

“…A combination of nab-paclitaxel plus gemcitabine (N+G) has recently become a standard first-line treatment in patients with metastatic pancreatic…”
Get full text

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial by Aparicio, Thomas, Bouché, Olivier, Etienne, Pierre-Luc, Barbier, Emilie, Mineur, Laurent, Desgrippes, Romain, Guérin-Meyer, Véronique, Hocine, Fayçal, Martin, Jean, Le Brun-Ly, Valérie, Cretin, Jacques, Desramé, Jérôme, Rinaldi, Yves, Cany, Laurent, Falandry, Claire, Lefevre, Leila Bengrine, Marous, Miguelle, Terrebonne, Eric, Mosser, Laurent, Turpin, Justine, Turpin, Anthony, Bauguion, Lucille, Reichling, Cynthia, Van den Eynde, Marc, Carola, Elisabeth, Hiret, Sandrine

“…Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant chemotherapy improved disease-free survival after stage III colon cancer…”
Get full text

Simplified Prognostic Model in Patients with Oxaliplatin‐Based or Irinotecan‐Based First‐Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study by Chibaudel, Benoist, Bonnetain, Franck, Tournigand, Christophe, Bengrine‐Lefevre, Leila, Teixeira, Luis, Artru, Pascal, Desramé, Jérôme, Larsen, Annette K., André, Thierry, Louvet, Christophe, Gramont, Aimery

“…Learning Objectives After completing this course, the reader will be able to: Describe prognostic factors in metastatic colorectal cancer. Estimate prognostic…”
Get full text